Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials

被引:98
作者
Machado, Marcio
Iskedjian, Michael
Ruiz, Ines
Einarson, Thomas R.
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5S 3M2, Canada
[2] Pharmideas Res & Consulting Inc, Oakville, ON, Canada
[3] Univ Chile, Santiago, Chile
关键词
antidepressants; dropout rates; head-to-head trials; major depressive disorder; meta-analysis; remission rates;
D O I
10.1185/030079906X132415
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To summarize remission rates and dropouts due to adverse drug reactions (ADRs) or lack of efficacy (LoE) of serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin-reuptake inhibitors (SSRIs), and tricyclic antidepressants (TCAs) in treating major depressive disorder. Methods: We searched MEDLINE, EMBASE, IPA, and the Cochrane International Library from 1980-2005. Meta-analysis summarized outcomes from head-to-head randomized clinical trials comparing ! 2 drugs from three antidepressants classes (SNRIs, and/or SSRIs, and/or TCAs) followed by ! 6 weeks of treatment. Remission was a final Hamilton Depression Rating Scale (HAMD) score <= 7 or Montgomery-Asberg Depression Rating Scale (MADRS) <= 12. Intent-to-treat data were combined across study arms using random effects models, producing point estimates with 95% confidence intervals. Results: We obtained data from 30 arms of 15 head-to-head trials with 2458 patients. SNRIs had the highest ITT remission rate (49.0%), then TCAs (44.11%), and SSRIs (37.7%) (p > 0.05 for SNRIs versus TCAs; p < 0.001 for TCAs versus SSRIs and SNRIs versus SSRIs). When categorized as inpatients (n = 582) and outpatients (n = 1613), SNRIs had the highest remission rates (52.0% for 144 inpatients and 49.3% for 559 outpatients). SNRIs had lowest overall dropouts (26.1%), followed by SSRIs (28.4%), and TCAs (35.7%). Dropouts due to ADRs and LoE were 10.3% and 6.2% for SNRIs, 8.3% and 7.2% for SSRIs, and 19.8% and 9.9% for TCAs, respectively (p > 0.05 for ADR dropouts only). One limitation was the inclusion of only venlafaxine-XR; results may not be the same for immediate release forms. In addition, few studies reported remission rates. Conclusions: SNRIs had the highest efficacy remission rates (statistically significant for inpatients and outpatients), and the lowest overall dropout rates, suggesting clinical superiority in treating major depression.
引用
收藏
页码:1825 / 1837
页数:13
相关论文
共 73 条
  • [1] Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram
    Allard, P
    Gram, L
    Timdahl, K
    Behnke, K
    Hanson, M
    Sogaard, J
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2004, 19 (12) : 1123 - 1130
  • [2] AMERONGEN APF, 2002, J AFFECT DISORDERS, V72, P21
  • [3] AMORE M, 1989, CURR THER RES CLIN E, V46, P815
  • [4] Andersen B, 1990, J AFFECT DISORDERS, V18, P289
  • [5] [Anonymous], 1987, DIAGNOSTIC STAT MANU, V4th
  • [6] CONTROLLED COMPARISON OF 2 DOSES OF MILNACIPRAN (F-2207) AND AMITRIPTYLINE IN MAJOR DEPRESSIVE INPATIENTS
    ANSSEAU, M
    VONFRENCKELL, R
    MERTENS, C
    DEWILDE, J
    BOTTE, L
    DEVOITILLE, JM
    EVRARD, JL
    DENAYER, A
    DARIMONT, P
    DEJAIFFE, G
    MIREL, J
    MEURICE, E
    PARENT, M
    COUZINIER, JP
    DEMAREZ, JP
    SERRE, C
    [J]. PSYCHOPHARMACOLOGY, 1989, 98 (02) : 163 - 168
  • [7] CONTROLLED COMPARISON OF MILNACIPRAN AND FLUOXETINE IN MAJOR DEPRESSION
    ANSSEAU, M
    PAPART, P
    TROISFONTAINES, B
    BARTHOLOME, F
    BATAILLE, M
    CHARLES, G
    SCHITTECATTE, M
    DARIMONT, P
    DEVOITILLE, JM
    DEWILDE, J
    DUFRASNE, M
    GILSON, H
    EVRARD, JL
    DENAYER, A
    KREMER, P
    MERTENS, C
    SERRE, C
    [J]. PSYCHOPHARMACOLOGY, 1994, 114 (01) : 131 - 137
  • [8] A 12-WEEK DOUBLE-BLIND MULTICENTER STUDY OF PAROXETINE AND IMIPRAMINE IN HOSPITALIZED DEPRESSED-PATIENTS
    ARMINEN, SL
    IKONEN, U
    PULKKINEN, P
    LEINONEN, E
    MAHLANEN, A
    KOPONEN, H
    KOURULA, K
    RYYPPO, J
    KORPELA, V
    LEHTONEN, ML
    VARTIAINEN, H
    LEHTINEN, V
    TAMMINEN, T
    MANNICHE, PM
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1994, 89 (06) : 382 - 389
  • [9] Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders
    Baca, E
    Garcia-Garcia, M
    Porras-Chavarino, A
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2004, 28 (01) : 57 - 65
  • [10] Sertraline is more effective than imipramine in the treatment of non-melancholic depression:: Results from a multicentre, randomized study
    Baca, E
    de Chávez, MG
    García-Toro, M
    Pérez-Arnau, F
    Porras-Chavarino, A
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2003, 27 (03) : 493 - 500